DOCKET NO.: FCCC-0004 Application No.: 09/868,196 Office Action Dated: June 2, 2003

This listing of claims will replace all prior versions, and listings, of claims in the application.

## Listing of Claims:

1-44. (Canceled)

45. (Previously Amended) A method of treating or preventing mammary tumors, comprising administering a host in need thereof an amount of hCG effective to inhibit proliferation of mammary tumor cells.

46-53. (Canceled)

- 54. (Previously Added) The method of claim 45, wherein the mammary tumor is a clinically manifest mammary tumor.
- 55. (Previously Added) The method of claim 54, wherein the clinically manifest mammary tumor is a primary tumor.
- 56. (Previously Added) The method of claim 45, wherein the mammary tumor is a non-invasive carcinoma.
- 57. (Previously Added) The method of claim 56, wherein the carcinoma is ductal carcinoma in situ or lobular carcinoma in situ.

DOCKET NO.: FCCC-0004 Application No.: 09/868,196 Office Action Dated: June 2, 2003

58. (Previously Added) The method of claim 45, wherein the mammary tumor is an invasive carcinoma.

- 59. (Previously Added) The method of claim 58, wherein the carcinoma is tubular or lobular invasive carcinoma.
- 60. (Previously Added) The method of claim 54, wherein the clinically manifest mammary tumor is a metastatic mammary tumor.
- 61. (Previously Added) The method of claim 45, wherein the host is a premenopausal woman.
- 62. (Previously Added) The method of claim 45, wherein the host is a postmenopausal woman.
- 63. (Previously Added) The method of claim 45, combined with at least one other cancer therapy.
- 64. (Previously Added) The method of claim 63, wherein the at least one other cancer therapy is surgery or chemotherapy.
- 65. (Previously Added) The method of claim 45, wherein the mammary tumors comprise cells that are estrogen receptor-positive.

DOCKET NO.: FCCC-0004 Application No.: 09/868,196 Office Action Dated: June 2, 2003

66-69. (Canceled) /

- 70. (Previously Added) The method of claim 45, wherein the hCG is administered in an amount of 100 to 20,000 IU per day.
- 71. (Previously Added) The method of claim 45, wherein the hCG is administered in amount of 50 to 50,000 micrograms per day.
- 72. (Previously Added) The method of claim 71, wherein the hCG is administered in an amount of 250 to 3,000 micrograms per day.
- 73. (Previously Added) The method of claim 45, wherein the hCG is administered every second day.
- 74. (Previously Added) The method of claim 45, wherein the hCG is administered three times each week.
- 75. (Previously Added) The method of claim 45, wherein the hCG is administered for several weeks.
- 76. (Previously Added) The method of claim 75, wherein the hCG is administered for at least 12 weeks.

DOCKET NO.: FCCC-0004 Application No.: 09/868,196 Office Action Dated: June 2, 2003

77. (Previously Added) The method of claim 45, wherein the hCG is administered subcutaneously.

78. (Previously Added) The method of claim 45, wherein the hCG is administered in combination with Type 1 interferon.

79. (Canceled)

80. (Previously Added) The method of claim 45, wherein the hCG is recombinant hCG.

81-103. (Canceled)